JP2010539993A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539993A5 JP2010539993A5 JP2010528876A JP2010528876A JP2010539993A5 JP 2010539993 A5 JP2010539993 A5 JP 2010539993A5 JP 2010528876 A JP2010528876 A JP 2010528876A JP 2010528876 A JP2010528876 A JP 2010528876A JP 2010539993 A5 JP2010539993 A5 JP 2010539993A5
- Authority
- JP
- Japan
- Prior art keywords
- transcription factor
- vector
- protein
- vitro
- dendritic cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000623 proteins and genes Proteins 0.000 claims 24
- 108091023040 Transcription factor Proteins 0.000 claims 23
- 102000040945 Transcription factor Human genes 0.000 claims 23
- 210000004443 dendritic cell Anatomy 0.000 claims 23
- 102000004169 proteins and genes Human genes 0.000 claims 16
- 238000000338 in vitro Methods 0.000 claims 13
- 102000040430 polynucleotide Human genes 0.000 claims 12
- 108091033319 polynucleotide Proteins 0.000 claims 12
- 239000002157 polynucleotide Substances 0.000 claims 12
- 102000013462 Interleukin-12 Human genes 0.000 claims 11
- 108010065805 Interleukin-12 Proteins 0.000 claims 11
- 229940117681 interleukin-12 Drugs 0.000 claims 11
- 239000003446 ligand Substances 0.000 claims 10
- 230000001419 dependent effect Effects 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 4
- 108010057988 ecdysone receptor Proteins 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000004568 DNA-binding Effects 0.000 claims 1
- 241000710188 Encephalomyocarditis virus Species 0.000 claims 1
- 108010001515 Galectin 4 Proteins 0.000 claims 1
- 102100039556 Galectin-4 Human genes 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 102100033159 Transcription factor 19 Human genes 0.000 claims 1
- 101710119700 Transcription factor 19 Proteins 0.000 claims 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229930002330 retinoic acid Natural products 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 229960001727 tretinoin Drugs 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97822407P | 2007-10-08 | 2007-10-08 | |
| US97839407P | 2007-10-08 | 2007-10-08 | |
| US97850907P | 2007-10-09 | 2007-10-09 | |
| US97948007P | 2007-10-12 | 2007-10-12 | |
| US97948507P | 2007-10-12 | 2007-10-12 | |
| US99016707P | 2007-11-26 | 2007-11-26 | |
| US99068907P | 2007-11-28 | 2007-11-28 | |
| US99180707P | 2007-12-03 | 2007-12-03 | |
| US1908908P | 2008-01-04 | 2008-01-04 | |
| PCT/US2008/011563 WO2009048560A1 (en) | 2007-10-08 | 2008-10-08 | Engineered dendritic cells and uses for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014250257A Division JP5934776B2 (ja) | 2007-10-08 | 2014-12-10 | 遺伝子操作した樹状細胞および癌の治療のための使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010539993A JP2010539993A (ja) | 2010-12-24 |
| JP2010539993A5 true JP2010539993A5 (https=) | 2011-12-22 |
Family
ID=40549463
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010528876A Withdrawn JP2010539993A (ja) | 2007-10-08 | 2008-10-08 | 遺伝子操作した樹状細胞および癌の治療のための使用 |
| JP2014250257A Expired - Fee Related JP5934776B2 (ja) | 2007-10-08 | 2014-12-10 | 遺伝子操作した樹状細胞および癌の治療のための使用 |
| JP2016004584A Expired - Fee Related JP6290270B2 (ja) | 2007-10-08 | 2016-01-13 | 遺伝子操作した樹状細胞および癌の治療のための使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014250257A Expired - Fee Related JP5934776B2 (ja) | 2007-10-08 | 2014-12-10 | 遺伝子操作した樹状細胞および癌の治療のための使用 |
| JP2016004584A Expired - Fee Related JP6290270B2 (ja) | 2007-10-08 | 2016-01-13 | 遺伝子操作した樹状細胞および癌の治療のための使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20090123441A1 (https=) |
| EP (2) | EP2207874B1 (https=) |
| JP (3) | JP2010539993A (https=) |
| KR (3) | KR101740205B1 (https=) |
| CN (1) | CN101883845B (https=) |
| AU (1) | AU2008311292B9 (https=) |
| BR (1) | BRPI0818287A2 (https=) |
| CA (1) | CA2702058A1 (https=) |
| ES (2) | ES2636460T3 (https=) |
| HU (2) | HUE035406T2 (https=) |
| IL (1) | IL204841A (https=) |
| MX (1) | MX2010003720A (https=) |
| NZ (1) | NZ585190A (https=) |
| RU (3) | RU2484132C2 (https=) |
| WO (1) | WO2009048560A1 (https=) |
| ZA (1) | ZA201003163B (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009025866A1 (en) * | 2007-08-23 | 2009-02-26 | Intrexon Corporation | Methods and compositions for diagnosing disease |
| KR101666228B1 (ko) * | 2007-09-28 | 2016-10-13 | 인트렉손 코포레이션 | 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도 |
| HUE035406T2 (en) * | 2007-10-08 | 2018-05-02 | Intrexon Corp | Engineered dendritic cells and uses for the treatment of cancer |
| CN102575227A (zh) * | 2008-10-08 | 2012-07-11 | 英特瑞克斯顿股份有限公司 | 表达多种免疫调节剂的工程改造细胞及其应用 |
| SI2534242T1 (sl) | 2010-02-10 | 2016-08-31 | Immunicum Ab | Izboljšan sestavek za inhibicijo tumorske celične proliferacije |
| CA2794196A1 (en) * | 2010-03-23 | 2011-09-29 | Intrexon Corporation | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
| EP2555627A4 (en) * | 2010-04-06 | 2013-10-23 | John W Holaday | METHOD FOR TREATING CARCINOMA |
| CN102026031B (zh) * | 2010-12-28 | 2013-09-04 | 张朝晖 | 一种机顶盒 |
| CN102174479B (zh) * | 2011-03-02 | 2013-04-03 | 北京锤特生物科技有限公司 | 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用 |
| SG10201600912SA (en) * | 2011-03-04 | 2016-03-30 | Intrexon Corp | Vectors conditionally expressing protein |
| CA3061802C (en) * | 2011-09-08 | 2022-04-05 | Intrexon Corporation | Crystalline diacylhydrazine and the use thereof |
| CA3101783C (en) * | 2011-10-11 | 2023-01-31 | Universitat Zurich Prorektorat Mnw | Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy |
| US11951157B2 (en) | 2011-10-11 | 2024-04-09 | Universitat Zurich | Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody |
| US9662329B2 (en) | 2012-03-26 | 2017-05-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of survivin antagonists in polyomavirus-related disease |
| US10435470B2 (en) * | 2014-08-05 | 2019-10-08 | Cb Therapeutics, Inc. | Anti-PD-L1 antibodies |
| US10550194B2 (en) * | 2014-09-30 | 2020-02-04 | Intervet Inc. | PD-L1 antibodies binding canine PD-L1 |
| SG11201802912PA (en) | 2015-10-10 | 2018-05-30 | Intrexon Corp | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
| WO2017083750A1 (en) | 2015-11-11 | 2017-05-18 | Intrexon Corporation | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies |
| SG11201810640RA (en) | 2016-06-08 | 2018-12-28 | Intrexon Corp | Cd33 specific chimeric antigen receptors |
| UY37343A (es) | 2016-07-25 | 2018-02-28 | Intrexon Corp | Control del fenotipo en plantas |
| KR20190102259A (ko) | 2017-01-10 | 2019-09-03 | 인트렉손 코포레이션 | 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절 |
| US11753619B2 (en) | 2017-02-02 | 2023-09-12 | The Scripps Research Institute | Engineered cells and methods of use |
| AU2018222735B2 (en) * | 2017-02-17 | 2023-04-27 | George Todaro | Use of TGF alpha for the treatment of diseases and disorders |
| RU2645957C1 (ru) * | 2017-04-10 | 2018-02-28 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ лечения лучевых повреждений мочевого пузыря |
| EP3635132A4 (en) | 2017-06-07 | 2021-05-26 | Intrexon Corporation | EXPRESSION OF NOVEL CELL MARKERS |
| RU2663468C1 (ru) * | 2017-09-25 | 2018-08-06 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ лечения местно-распространенного нерезектабельного рака поджелудочной железы |
| WO2019173465A1 (en) | 2018-03-06 | 2019-09-12 | Intrexon Corporation | Human papillomavirus vaccines and uses of the same |
| IL277128B2 (en) | 2018-03-06 | 2025-11-01 | Precigen Inc | Hepatitis b vaccines and uses of the same |
| EP3810641A4 (en) * | 2018-06-19 | 2022-07-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | ONCOLYTIC VIRUS OR ANTIGEN PRESENT CELL MEDIATED CANCER THERAPY USING TYPE I INTERFERON AND CD40 LIGAND |
| CA3103372A1 (en) * | 2018-06-27 | 2020-01-02 | Precigen, Inc. | In vivo controlled combination therapy for treatment of cancer |
| CA3128973A1 (en) | 2019-03-04 | 2020-09-10 | Bhaskar Bhattacharyya | Data compression and communication using machine learning |
| WO2020206056A1 (en) | 2019-04-04 | 2020-10-08 | Greenvenus Llc | Peptides and methods of plant protection |
| CN110804594B (zh) * | 2019-11-21 | 2020-11-20 | 启辰生生物科技(珠海)有限公司 | 工程化抗原递呈细胞及其在用于活化cd3+免疫细胞中的应用 |
| EP4061485A4 (en) * | 2019-11-22 | 2023-12-20 | Alaunos Therapeutics, Inc. | METHOD FOR TREATING GLIOBLASTOMA |
| CN115867643A (zh) * | 2020-03-16 | 2023-03-28 | 布鲁塞尔自由大学 | 增强树突细胞效力的mRNA混合物 |
| WO2023023503A1 (en) * | 2021-08-16 | 2023-02-23 | Yale University | Interleukin-12 variants and methods of use |
| CN114480280B (zh) * | 2022-03-02 | 2023-09-29 | 中国科学院理化技术研究所 | 烟草花叶病毒在刺激巨噬细胞极化为m1型巨噬细胞中应用 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4985461A (en) * | 1985-10-21 | 1991-01-15 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
| US5117057A (en) | 1985-10-21 | 1992-05-26 | Rohm And Haas Company | Insecticidal N' substituted-N-N'-disubstituted-hydrazines |
| FR2593630B1 (fr) | 1986-01-27 | 1988-03-18 | Maurice Francois | Ecran d'affichage a matrice active a resistance de drain et procedes de fabrication de cet ecran |
| US5225443A (en) | 1986-05-01 | 1993-07-06 | Rohm And Haas Company | Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines |
| US4981784A (en) | 1987-12-02 | 1991-01-01 | The Salk Institute For Biological Studies | Retinoic acid receptor method |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5693622A (en) * | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| CA2043775A1 (en) | 1990-06-14 | 1991-12-15 | Dat P. Le | Dibenzoylakylcyanohydrazines |
| IL100643A (en) | 1991-01-25 | 1996-10-31 | Nippon Kayaku Kk | History of hydrazine and pesticides containing these histories as an active ingredient |
| US6013836A (en) | 1992-02-28 | 2000-01-11 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-disubstitutedhydrazines |
| US5530028A (en) | 1992-11-23 | 1996-06-25 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
| US5814618A (en) * | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5834441A (en) * | 1993-09-13 | 1998-11-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral (AAV) liposomes and methods related thereto |
| US6652850B1 (en) * | 1993-09-13 | 2003-11-25 | Aventis Pharmaceuticals Inc. | Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity |
| EP0729511A1 (en) * | 1993-11-18 | 1996-09-04 | Chiron Corporation | Compositions and methods for utilizing conditionally lethal genes |
| FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| US5573764A (en) * | 1994-01-21 | 1996-11-12 | Genetics Institute, Inc. | Use of interleukin-12 to prevent graft versus host disease |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| US6306649B1 (en) * | 1995-06-27 | 2001-10-23 | Ariad Gene Therapeutics, Inc. | Heterologous transcription factors |
| US7176186B1 (en) * | 1997-09-16 | 2007-02-13 | The University Of Pittsburgh Of The Commonwealth System Of Higher Education | Stimulation of cell-mediated immune responses by targeted particulate genetic immunization |
| US6734014B1 (en) | 1996-02-08 | 2004-05-11 | The United States Of America As Represented By The Department Of Health And Human Services | Methods and compositions for transforming dendritic cells and activating T cells |
| US6723531B2 (en) | 1996-04-05 | 2004-04-20 | The Salk Institute For Biological Studies | Method for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| US5922685A (en) * | 1996-06-05 | 1999-07-13 | Powderject Vaccines, Inc. | IL-12 gene therapy of tumors |
| BR9709715A (pt) * | 1996-06-14 | 1999-08-10 | Bayer Ag | Agonistas de interleucina-4 seletivos para células t |
| CA2269642A1 (en) * | 1996-10-29 | 1998-05-07 | Valentis, Inc. | Modified glucocorticoid receptors, glucocorticoid receptors/progesterone receptors hybrids |
| ES2278399T3 (es) * | 1996-11-20 | 2007-08-01 | Introgen Therapeutics, Inc. | Metodo mejorado para la produccion y purificacion de vectores adenovirales. |
| US5972986A (en) * | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
| US6899870B1 (en) * | 1998-03-11 | 2005-05-31 | Board Of Regents, The University Of Texas System | Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery |
| US7279565B2 (en) * | 1998-05-05 | 2007-10-09 | Richard Voellmy | Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| US6342596B1 (en) * | 1998-05-05 | 2002-01-29 | Hsf Pharmaceuticals S.A. | Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| US6333318B1 (en) | 1998-05-14 | 2001-12-25 | The Salk Institute For Biological Studies | Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
| US6258603B1 (en) | 1998-06-17 | 2001-07-10 | Rohm And Haas Company | Ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| WO2000015264A1 (en) * | 1998-09-15 | 2000-03-23 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | In situ injection of antigen-presenting cells with genetically enhanced cytokine expression |
| ID30407A (id) * | 1999-05-13 | 2001-11-29 | American Cyanamid Co | Formulasi-formulasi kombinasi bahan penambah |
| US6630324B1 (en) * | 1999-07-29 | 2003-10-07 | Baylor College Of Medicine | Aldehyde reductase bidirectional promoter and its use |
| US6774226B1 (en) * | 1999-11-30 | 2004-08-10 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
| JP5031967B2 (ja) * | 2000-03-22 | 2012-09-26 | イントレキソン コーポレーション | 新規エクジソン受容体ベースの誘導性遺伝子発現系 |
| US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
| RU2192263C2 (ru) * | 2000-08-17 | 2002-11-10 | Российский научно-исследовательский нейрохирургический институт им. проф. А.Л.Поленова | Способ лечения злокачественных опухолей головного мозга |
| PE20020322A1 (es) * | 2000-08-18 | 2002-05-10 | Pharmacia Corp | Formulacion oral de rapida disolucion de un inhibidor de la ciclooxigenasa 2 |
| US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
| ES2424812T3 (es) * | 2001-02-20 | 2013-10-08 | Intrexon Corporation | Receptores X retinoides quiméricos y su uso en un sistema inducible de expresión génica basado en receptores de ecdisona novedoso |
| EP1373470B1 (en) * | 2001-02-20 | 2013-04-24 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| WO2002066613A2 (en) | 2001-02-20 | 2002-08-29 | Rheogene Holdings, Inc | Novel ecdysone receptor/invertebrate retinoid x receptor-based inducible gene expression system |
| CA2438133C (en) | 2001-02-20 | 2015-01-27 | Rheogene, Inc. | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| CA2349506C (en) * | 2001-06-14 | 2009-12-08 | Duke University | A method for selective expression of therapeutic genes by hyperthermia |
| US7375093B2 (en) * | 2002-07-05 | 2008-05-20 | Intrexon Corporation | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US20080050808A1 (en) * | 2002-10-09 | 2008-02-28 | Reed Thomas D | DNA modular cloning vector plasmids and methods for their use |
| US7785871B2 (en) | 2002-10-09 | 2010-08-31 | Intrexon Corporation | DNA cloning vector plasmids and methods for their use |
| JP2006505280A (ja) * | 2002-11-07 | 2006-02-16 | チャン・ルン−ジ | 改変樹状細胞 |
| GB0228465D0 (en) * | 2002-12-06 | 2003-01-08 | Univ Belfast | A method of treating disease |
| US7304161B2 (en) | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
| US7304162B2 (en) | 2003-02-21 | 2007-12-04 | Intrexon Corporation | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US7456315B2 (en) * | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| US20070059828A1 (en) * | 2003-11-07 | 2007-03-15 | Tetsuji Yamaoka | Carrier for nucleic acid molecule delivery |
| US20050130306A1 (en) * | 2003-12-10 | 2005-06-16 | Richard Voellmy | Viral vectors whose replication and, optionally, passenger gene are controlled by a gene switch activated by heat in the presence or absence of a small molecule regulator |
| US7935510B2 (en) * | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| US20090170727A1 (en) | 2004-05-18 | 2009-07-02 | Intrexon Corporation | Methods for dynamic vector assembly of dna cloning vector plasmids |
| US9034650B2 (en) | 2005-02-02 | 2015-05-19 | Intrexon Corporation | Site-specific serine recombinases and methods of their use |
| WO2007084364A2 (en) * | 2006-01-13 | 2007-07-26 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health | Improved il-12 for expression in mammalian cells |
| CN104761466A (zh) * | 2007-05-29 | 2015-07-08 | 英特拉克森公司 | 通过蜕皮素受体复合物调节外源性基因表达的手性二酰基肼配体 |
| KR101666228B1 (ko) * | 2007-09-28 | 2016-10-13 | 인트렉손 코포레이션 | 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도 |
| HUE035406T2 (en) * | 2007-10-08 | 2018-05-02 | Intrexon Corp | Engineered dendritic cells and uses for the treatment of cancer |
-
2008
- 2008-10-08 HU HUE13175597A patent/HUE035406T2/en unknown
- 2008-10-08 BR BRPI0818287A patent/BRPI0818287A2/pt not_active Application Discontinuation
- 2008-10-08 KR KR1020167010116A patent/KR101740205B1/ko not_active Expired - Fee Related
- 2008-10-08 US US12/247,738 patent/US20090123441A1/en not_active Abandoned
- 2008-10-08 NZ NZ585190A patent/NZ585190A/xx not_active IP Right Cessation
- 2008-10-08 WO PCT/US2008/011563 patent/WO2009048560A1/en not_active Ceased
- 2008-10-08 AU AU2008311292A patent/AU2008311292B9/en not_active Ceased
- 2008-10-08 ES ES13175597.7T patent/ES2636460T3/es active Active
- 2008-10-08 EP EP08836827.9A patent/EP2207874B1/en not_active Not-in-force
- 2008-10-08 HU HUE08836827A patent/HUE024479T2/en unknown
- 2008-10-08 KR KR1020177013507A patent/KR101932027B1/ko not_active Expired - Fee Related
- 2008-10-08 CA CA2702058A patent/CA2702058A1/en not_active Abandoned
- 2008-10-08 JP JP2010528876A patent/JP2010539993A/ja not_active Withdrawn
- 2008-10-08 EP EP13175597.7A patent/EP2674483B1/en not_active Not-in-force
- 2008-10-08 ES ES08836827.9T patent/ES2531522T3/es active Active
- 2008-10-08 CN CN200880119203.5A patent/CN101883845B/zh not_active Expired - Fee Related
- 2008-10-08 RU RU2010118428/10A patent/RU2484132C2/ru active
- 2008-10-08 MX MX2010003720A patent/MX2010003720A/es active IP Right Grant
- 2008-10-08 KR KR1020107010283A patent/KR101655487B1/ko not_active Expired - Fee Related
-
2010
- 2010-04-06 IL IL204841A patent/IL204841A/en active IP Right Grant
- 2010-05-05 ZA ZA2010/03163A patent/ZA201003163B/en unknown
-
2011
- 2011-09-01 US US13/224,091 patent/US20120114620A1/en not_active Abandoned
-
2013
- 2013-01-09 US US13/737,316 patent/US9675642B2/en active Active
- 2013-02-15 RU RU2013106702A patent/RU2644210C2/ru not_active IP Right Cessation
-
2014
- 2014-12-10 JP JP2014250257A patent/JP5934776B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-13 JP JP2016004584A patent/JP6290270B2/ja not_active Expired - Fee Related
-
2017
- 2017-05-10 US US15/591,468 patent/US20170312315A1/en not_active Abandoned
- 2017-12-28 RU RU2017146770A patent/RU2711606C2/ru active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010539993A5 (https=) | ||
| RU2013106702A (ru) | Модифицированные дендритные клетки и их применение в лечении злокачественных опухолей | |
| Barczak et al. | Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response | |
| JP6686008B2 (ja) | がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法 | |
| Prensner et al. | The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer | |
| Moreau et al. | Non‐classical transcriptional regulation of HLA‐G: an update | |
| CN114207134B (zh) | 工程化的mRNA序列及其用途 | |
| JP2021153589A (ja) | クローディン−１８．２−特異的免疫受容体およびｔ細胞エピトープ | |
| JP2021518160A5 (https=) | ||
| JP2020532291A5 (https=) | ||
| ATE466872T1 (de) | An mhc-moleküle bindende tumor-assoziierte peptide | |
| JP2017525336A5 (https=) | ||
| WO2020186207A3 (en) | Non-viral dna vectors and uses thereof for expressing fviii therapeutics | |
| AU2016204658A1 (en) | Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct | |
| JP2020535845A5 (https=) | ||
| Dunker et al. | Expression and regulation of non‐classical HLA‐G in renal cell carcinoma | |
| JP2015504071A5 (https=) | ||
| JP2006505266A (ja) | 幹細胞の増幅因子 | |
| MX2022011805A (es) | Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con factor ix. | |
| CN114729320A (zh) | 用于将细胞重新程序化为能够呈递抗原的树突细胞2型的组合物、方法及其用途 | |
| Ojo et al. | Gfi1 controls the formation of effector-like CD8+ T cells during chronic infection and cancer | |
| JPWO2021226151A5 (https=) | ||
| CN111971394A (zh) | 嵌合抗原受体的肿瘤环境特异性表达 | |
| JP2006511212A5 (https=) | ||
| DK1760153T3 (da) | Adenovirus-/alfavirus-hybridvektor til effektiv administrering og expression af terapeutiske gener i tumorceller |